T 0036/23 (Production of oligonucleotides/GSK) vom 01.04.2025
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2025:T003623.20250401
- Datum der Entscheidung
- 1. April 2025
- Aktenzeichen
- T 0036/23
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 17739936.7
- IPC-Klasse
- C07H 1/00C07H 21/00C12N 9/00
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Novel processes for the production of oligonucleotides
- Name des Antragstellers
- GlaxoSmithKline Intellectual Property Development Limited
- Name des Einsprechenden
- JG Oppositions Limited
Janssen Pharmaceutica N.V. - Kammer
- 3.3.08
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 100(b)European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Schlagwörter
- Sufficiency of disclosure - (no)
Sufficiency of disclosure - undue burden (yes)
Amendment to case - reasons for submitting amendment in appeal proceedings (no)
Late-filed evidence - should have been submitted in first-instance proceedings (yes)
Late-filed evidence - circumstances of appeal case justify admittance (no)
Statement of grounds of appeal - party's complete appeal case
Statement of grounds of appeal - reasons set out clearly and concisely (no)
Discretion not to admit submission - requirements of Art. 12(3) RPBA 2020 met (no) - Orientierungssatz
- -
- Zitierende Akten
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.